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Abstract
Background: Successful antiretroviral treatment programs in rural sub-Saharan Africa may face
different challenges than programs in urban areas. The objective of this study was to identify patient
characteristics, barriers to care, and treatment responses of HIV-infected children seeking care in
rural Zambia.
Methods: Cross-sectional analysis of HIV-infected children seeking care at Macha Hospital in rural
southern Zambia. Information was collected from caretakers and medical records.
Results: 192 HIV-infected children were enrolled from September 2007 through September 2008,
28% of whom were receiving antiretroviral therapy (ART) at enrollment. The median age was 3.3
years for children not receiving ART (IQR 1.8, 6.7) and 4.5 years for children receiving ART (IQR
2.7, 8.6). 91% travelled more than one hour to the clinic and 26% travelled more than 5 hours. Most
participants (73%) reported difficulties accessing the clinic, including insufficient money (60%), lack
of transportation (54%) and roads in poor condition (32%). The 54 children who were receiving
ART at study enrollment had been on ART a median of 8.6 months (IQR: 2.7, 19.5). The median
percentage of CD4+ T cells was 12.4 (IQR: 9.2, 18.6) at the start of ART, and increased to 28.6
(IQR: 23.5, 36.1) at the initial study visit. However, the proportion of children who were
underweight decreased only slightly, from 70% at initiation of ART to 61% at the initial study visit.
Conclusion: HIV-infected children in rural southern Zambia have long travel times to access care
and may have poorer weight gain on ART than children in urban areas. Despite these barriers,
these children had a substantial rise in CD4+ T cell counts in the first year of ART although longer
follow-up may indicate these gains are not sustained.
Background
An estimated 2 million children under the age of 15 were
living with HIV infection at the end of 2007, with almost
90% residing in sub-Saharan Africa [1]. Since the World
Health Organization launched the '3 by 5' campaign in
2003 [2], dramatic improvements have been made to
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increase access to life-prolonging treatment for children in
developing countries, with the number of children in sub-
Saharan Africa receiving antiretroviral therapy increasing
from approximately 50,000 in 2005 to over 150,000 by
the end of 2007 [3].
Despite initial reservations about the implementation of
antiretroviral treatment programs in Africa [4,5], recent
reports demonstrate that treatment programs for HIV-
infected children in sub-Saharan Africa can achieve out-
comes similar to those in North America and Europe [6].
However, as the rollout of ART continues, concerns have
been raised about how equitably access to ART has been
distributed within countries [7-9]. HIV care services have
primarily been implemented in urban areas and have
lagged behind in rural areas, where there are shortages of
trained personnel and the health care system faces many
challenges [10]. Barriers faced by residents in rural areas
may prevent them from accessing HIV care, including
lower treatment literacy [11], greater distances and travel
times to clinics [3], and fewer financial resources for trans-
portation [12,13].
To address these issues, decentralized models for health
care delivery have been developed to increase access to
care in several rural settings [14-18]. Initial reports from
rural programs have been promising [16-20]; however,
further evaluation of rural HIV care programs is needed to
understand the challenges to the care and treatment of
HIV-infected persons, particularly children. We evaluated
barriers to the care of HIV-infected children attending an
HIV clinic in rural southern Zambia, with the goal of
developing strategies to optimize the care of these chil-
dren.
Methods
Study setting and population
HIV-infected children younger than 16 years and attend-
ing the Antiretroviral Clinic at Macha Hospital in Macha,
Zambia were eligible for enrollment. Macha is located in
Southern Province, approximately 80 km from the nearest
town of Choma. The catchment area of Macha Hospital is
populated by traditional villagers living in small, scattered
homesteads, with an estimated population density of 25
persons per km2 (P. Thuma, unpublished data). Macha
Hospital is a 208-bed hospital administered by the Zam-
bian Brethren in Christ Church that functions within the
healthcare system of the Ministry of Health. The hospital
serves as a district-level referral hospital for smaller hospi-
tals and rural health centers within an 80 km radius, serv-
ing a population of over 150,000 persons. Macha
Hospital provides care to approximately 4000 HIV-
infected adults and children through the Government of
Zambia's antiretroviral treatment program, with addi-
tional support from the President's Emergency Plan for
AIDS Relief (PEPFAR) through the non governmental
organization, AidsRelief. A program to prevent maternal-
to-child HIV transmission began at Macha Hospital
simultaneous with the implementation of the ART clinic
in 2005.
HIV-infected children are referred to the clinic from vol-
untary counseling and testing programs, outpatient clinics
and hospitals. Since February 2008, children born to HIV-
infected women are routinely tested for HIV infection at
approximately 6 weeks of age, using dried blood spot
samples and HIV DNA PCR performed in Lusaka, Zambia.
Clinical care is provided without charge by medical doc-
tors and clinical officers, and adherence counseling by
nurses and trained counselors. Home visits are attempted
for persons who fail to return for scheduled follow-up vis-
its. Children were considered eligible for antiretroviral
therapy if they had WHO stage 3 or 4 disease, or a CD4+ T
cell percentage of <25% for children ≤ 11 months of age,
< 20% for children 12-35 months of age, or <15% for chil-
dren ≥ 36 months of age. The first-line antiretroviral treat-
ment regimen consists of two nucleoside reverse
transcriptase inhibitors (lamivudine plus zidovudine or
stavudine) and a non-nucleoside reverse transcriptase
inhibitor (efavirenz or nevirapine).
Study procedures
This cross-sectional analysis was conducted within the
context of an observational cohort study. HIV-infected
children seeking outpatient care at Macha Mission Hospi-
tal, Choma, Zambia were prospectively enrolled into an
observational cohort study beginning in September 2007
after written informed consent was obtained from a par-
ent or guardian. The caretakers of all children who were
asked to participate agreed to enroll in the study. A ques-
tionnaire developed by the study team was administered
to the parent or guardian and the child was examined at
the initial study visit and at each follow-up visit occurring
approximately every three months. Blood specimens were
collected in EDTA tubes as part of routine clinical care.
Information from before study enrollment was abstracted
from medical records. CD4+ T cell counts and percentages
were measured using the Guava Easy CD4 system (Guava
Technologies, Inc., Hayward, CA), and hemoglobin was
measured using the ABX MICROS 60 (Hariba ABX,
France). The study was approved by the Research Ethics
Committee of the University of Zambia, the Ministry of
Health, Republic of Zambia and the Institutional Review
Board of the Johns Hopkins Bloomberg School of Public
Health.
For the present analysis, information was used from the
initial study visit for HIV-infected children enrolled into
the cohort study between September 2007 and September
2008. Children were classified as HIV-infected if they wereBMC Infectious Diseases 2009, 9:169 http://www.biomedcentral.com/1471-2334/9/169
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older than 18 months with a positive serological test,
younger than 18 months with confirmed infection by PCR
either prior to or within 3 months of the initial study visit,
or younger than 18 months with a positive serological test
and either eligible for ART based on the 2006 WHO treat-
ment guidelines or receiving ART at the initial study visit.
Statistical Analysis
Data were entered in duplicate using EpiInfo (Centers for
Disease Control and Prevention) and analyses were con-
ducted in SAS for Windows version 9.1 (SAS Institute Inc.,
Cary, NC). Proportions are reported for categorical varia-
bles and differences were tested using chi-square tests.
Medians and interquartile ranges are reported for contin-
uous variables and differences were tested using Wilcoxon
rank sum tests.
Children were categorized according to their use of ART at
the time of the first study visit. Children who were not on
ART were further categorized by eligibility for ART, as
defined by the 2006 WHO treatment guidelines [21]. If
laboratory results were not available at a specified clinic
visit, results were used within a 3-month period (3
months prior for children initiating ART). Weight-for-age
z-scores were calculated based on the WHO growth stand-
ards [22] and children with z-scores below -2 were defined
as underweight. A measure of socio-economic status (SES)
was calculated based on the Demographic and Health
Survey SES scale used in Zambia [23]. SES percentiles were
based on the predetermined cutoffs (<25th = 0-6; 26-50th
= 7-12; 51-75th = 13-18; >75th = 19-24).
Results
Characteristics of study children
192 HIV-infected children were enrolled, 54 (28%) of
whom were receiving ART at the initial study visit. These
children represent approximately 70% of all HIV-infected
children with at least one clinic visit between September
2007 and September 2008. The median age was 3.5 years
(IQR: 1.9, 7.4; range: 0.3, 15.6) and 47% were boys (Table
1). The majority of children were cared for by a parent
(74%), although 35% had lost one or both parents, and
the majority of parents (96%) reported signs and symp-
toms of disease at the time of the initial clinic visit. Most
children whose primary caregiver was not a parent were
cared for by other family members, primarily a grandpar-
ent. The median age of the primary caregiver was 35.8
years (IQR: 30.3, 43.6) and their educational status was
low, with 61% of caregivers achieving at most a primary
level of education, and only 52% of these caregivers com-
pleted grade 7. The socioeconomic status of the house-
holds also was low, with 70% of children living below the
25th percentile. Children receiving ART at the initial study
visit were older (median age: 4.5 vs. 3.3 years) and were
more likely to be male (67% vs. 40%), but were otherwise
similar to children who were not receiving ART at the ini-
tial study visit. The use of antiretrovirals to prevent
mother-to-child transmission in the study population was
uncommon; seven children (4%), none of whom were
receiving ART, received antiretrovirals in the perinatal
period as confirmed by the medical record (n = 6) or self-
report (n = 1).
Disclosure of HIV-infection status
As the study population was young, few children (3%)
were reported to be aware of their HIV infection status.
Among older children, only 5 (17%) of 29 children older
than 10 years were aware of their status, with significantly
more children receiving ART aware of their status (33% vs.
6%; P = 0.05). Of those children who were not informed
of their HIV infection status, 83% were reported to be
aware that they were sick (88% on ART vs. 81% not on
ART; P = 0.70). Caregivers were asked to provide reasons
for non-disclosure, and the primary reason (88%) was
because they felt the child was too young to know. Forty-
two percent of caregivers also reported that they had not
disclosed the child's status because they were afraid to tell
the child, 21% because they did not know how to tell the
child, and 17% because they felt that it was not good for
the child to know their HIV infection status.
Among all caregivers, 97% reported that someone other
than themselves or the child was aware of the child's HIV
infection status, with 47% reporting that only other fam-
ily members had been told, 49% reporting that family
members as well as others in the community (mostly
neighbors) had been told, and 1% reporting that only
other non-family members had been told. Significantly
more caregivers of children on ART had disclosed to both
family members and others in the community compared
to children not receiving treatment (86% vs. 36%, P <
0.0001). Few caregivers (2%) reported being fearful of
others finding out about their child's HIV infection status,
or felt that they (3%) or their children (6%) were stigma-
tized because of their child's status. Significantly more car-
egivers of children on ART reported that they (9% vs. 1%,
P = 0.004) or their child (16% vs. 2%, P = 0.0008) had
been stigmatized. Among caregivers who reported feeling
stigmatized, their children primarily experienced rejection
by family (60%) and friends (50%), while the caregivers
experienced rejection by their family (60%) and commu-
nity (60%).
Clinic access
Children and their caregivers travelled an estimated
median distance of 28 km (IQR: 18, 45) to attend the
clinic. The majority of participants used a single mode of
transportation, including walking (30%), cycling (39%)
or public transportation (31%). The majority (91%) of
participants travelled more than one hour to the clinic,BMC Infectious Diseases 2009, 9:169 http://www.biomedcentral.com/1471-2334/9/169
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with 26% travelling more than 5 hours (Figure 1). For par-
ticipants who used motorized vehicles, 53% spent more
than 20,000 ZMK (approximately 5 USD at that time) of
their own (54%) or their family's (46%) money for trans-
portation. No significant differences were found in mode,
time or cost of transportation between children who were
and were not receiving ART at study enrollment.
Seventy-three percent of participants reported ever experi-
encing problems accessing the clinic (Figure 2), primarily
due to lack of money (60%), transportation (54%), and
because roads were in poor condition (32%). No caretak-
ers reported problems attending the clinic due to lack of
time, forgetting about appointments or inability to find
childcare. Caretakers tended to report more problems
accessing the clinic during the rainy season (78%) from
mid-November to mid-April than during the dry season
(67%, P = 0.2). Significantly more children not receiving
ART reported problems attending the clinic than children
receiving ART (79% vs. 59%, P = 0.01).
Characteristics of children not receiving ART at the initial 
study visit
138 HIV-infected children were not receiving ART at study
enrollment (Table 2). These children had been followed
in the clinic a median of 3.2 months before study enroll-
Table 1: Characteristics of HIV-infected children in the ART clinic in Macha, Zambia (2007 to 2008)
Total
(n = 192)
Not on ART
(n = 138)
On ART
(n = 54)
Child
Median age in years (IQR)a 3.5 (1.9, 7.4) 3.3 (1.8, 6.7) 4.5 (2.7, 8.6)
Male (%)a 91 (47) 55 (40) 36 (67)
Parents
Status (%)
Both alive 121 (65) 94 (69) 27 (54)
Mother deceased 26 (14) 20 (15) 6 (12)
Father deceased 19 (10) 11 (8) 8 (16)
Both deceased 20 (11) 11 (8) 9 (18)
Primary Caregiver
Relationship to child (%)
Mother/father 139 (74) 104 (76) 35 (70)
Grandparent 28 (15) 17 (12) 11 (22)
Aunt/uncle 14 (7) 11 (8) 3 (6)
Sibling 3 (2) 2 (1) 1 (2)
Other 3 (2) 3 (2) 0 (0)
Median age (IQR)b 35.8 (30.3, 43.6) 35.5 (29.2, 43.6) 38.0 (33.3, 43.5)
Education (%)b
None 8 (5) 5 (4) 3 (7)
Primary 98 (56) 75 (58) 23 (52)
Secondary 64 (37) 46 (35) 18 (41)
Higher 4 (2) 4 (3) 0 (0)
Household SES (%)
≤25th percentile 131 (70) 97 (71) 34 (68)
26-50th percentile 48 (26) 33 (24) 15 (30)
51-75th percentile 7 (4) 6 (4) 1 (2)
76-100th percentile 1 (1) 1 (1) 0 (0)
Travel to ART clinic
Median distance in km
IQR)
28 (18-45) 28 (17-45) 30 (18-42)
ART = antiretroviral therapy; IQR = interquartile range; SES = socioeconomic status
ap < 0.05 for difference between HIV-infected children on ART and not yet on ART
bexcluding respondents who are not the child's primary caregiver (n = 13)BMC Infectious Diseases 2009, 9:169 http://www.biomedcentral.com/1471-2334/9/169
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ment (IQR: 0.5, 10.1). The median percentage of CD4+ T
cells was 20.7 (IQR: 16.0, 30.0), but 37% of children were
severely immunosuppressed. In addition, 54% of children
were classified as WHO stage 3 or 4 at the initial study
visit. In this group, 79 (60%) children were eligible at the
initial study visit to start treatment based on the 2006
WHO treatment guidelines [21]. These children had been
followed in the clinic a median of 2.8 months (IQR: 0.4,
9.0), and for 14% of children this visit represented their
first visit in the clinic. Children eligible for treatment were
significantly younger (2.3 vs. 3.6), had lower median
WAZ (-2.4 vs. -2.1), and, as expected, had a lower median
percentage of CD4+ T cells (17.4 vs. 29.6) and higher stage
of disease progression (78% classified as WHO stage 3 or
4 vs. 0%). Based upon detailed review of the medical
records of those children deemed eligible for ART at the
initial study visit and who had been followed at the clinic
a sufficient length of time to have a potential delay in ini-
tiation of ART, the most common reasons for a potential
delay were loss to follow-up (10 children), concurrent
tuberculosis (9 children) and need for adherence coun-
seling (3 children).
Response to therapy among children receiving ART at the 
initial study visit
54 children were receiving ART at study enrollment (Table
3). These children had been followed in the clinic a
median of 13.6 months (IQR: 6.4, 23.2) and had been on
ART a median of 8.6 months (IQR: 2.7, 19.5). The median
percentage of CD4+ T cells was 12.4 (IQR: 9.2, 18.6) at the
start of ART and increased to 28.6 (IQR: 23.5, 36.1) at the
initial study visit. The median increase in percentage of
CD4+ T cells from ART initiation to the initial study visit
was 18.1 (IQR: 6.0, 26.8). The percentage of CD4+ T cells
increased with the duration of ART use (Figure 3). The
proportion of children with a percentage of CD4+ T cells
greater than 25% increased from 64% among those who
had received ART for less than 12 months (n = 22) to 83%
among those who had received ART for at least 12 months
(n = 18). Children were not consistently classified accord-
ing to WHO clinical stage; however, among those with
WHO staging available (28 at ART initiation and 34 at the
initial study visit) there was a decrease in the proportion
of children in stage 3 or 4 from 89% at ART initiation to
65% at the initial study visit. However, the proportion of
children who were underweight decreased only slightly,
from 70% at ART initiation to 60.5% at the initial study
visit for 37 children with available data. WAZ scores
increased a median of 0.24 (IQR: -0.57, 0.84) from initia-
tion of ART to the initial study visit.
ART regimens and adherence
ART regimens at treatment initiation and the initial study
visit consisted of a combination of 2 NRTIs and 1 NNRTI.
Side effects were rarely reported, with only two children
reporting a rash and one child reporting headaches after
treatment initiation. A median of two adults (IQR: 2-3)
were involved in supervising the administration of ART.
The primary person responsible for ART administration
was the child's mother (56%). Sixty-one percent of chil-
dren were living in households where at least one other
person, primarily a parent, also was receiving ART. Among
respondents, 22% of 41 reported problems with adher-
ence. Among those who did, the primary reasons for a
child missing a dose were forgetting (n = 2), the pills being
either too numerous (n = 1) or too large to swallow (n =
1), the child refusing (n = 1), side effects (n = 2), the car-
egiver being away (n = 1), and finishing the supply of
drugs prior to the next clinic appointment (n = 1).
Method of transportation and travel time to the ART clinic  among HIV-infected children Figure 1
Method of transportation and travel time to the ART 
clinic among HIV-infected children. Note: Modes of 
transportation are not mutually exclusive.
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Problems experienced by HIV-infected children and their  caregivers in travelling to the ART clinic in Macha, Zambia Figure 2
Problems experienced by HIV-infected children and 
their caregivers in travelling to the ART clinic in 
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Discussion
Most assessments of the care of HIV-infected children in
sub-Saharan Africa have been from urban sites, often from
established research programs [6]. Our observations high-
light barriers to the care of HIV-infected children unique
to rural settings, specifically long travel times and lack of
transportation, but are encouraging in that age at clinic
enrollment and immunologic outcomes in the first year of
treatment did not differ substantially from published
reports on the care of HIV-infected children in urban sub-
Saharan Africa. These findings suggest that the barriers to
the care of HIV-infected children in rural settings do not
pose insurmountable obstacles to desirable treatment
outcomes.
The median age of HIV-infected children receiving care in
rural southern Zambia was younger than commonly
reported (4.5 years for children receiving ART and 3.3
years for children not receiving ART). Among studies
reporting the effectiveness of pediatric ART in sub-Saha-
ran Africa, 73% of 26 studies reported a median or mean
age of five years or older at initiation of ART [6]. In Lusaka,
Zambia, the median age at which HIV-infected children
began care was 5.4 years (IQR: 1.9, 9.5) [24]. Thus, com-
pared to this urban Zambian pediatric cohort, children
accessing care in this rural setting do not appear to face
additional delays; however, the number of children undi-
agnosed or not accessing care is not known. There is
urgent need to diagnose HIV infection and initiate ART
within the first year of life given the high mortality rate in
early childhood [25] and the demonstrated benefits of ini-
tiating treatment in early infancy [26]. In rural Zambia, as
elsewhere in sub-Saharan Africa, children accessing care
are a subset of HIV-infected children with slower disease
progression. At Macha Hospital, infant diagnosis of HIV
infection using dried blood spots and PCR was introduced
in February 2008, and is likely to reduce the age at which
HIV-infected children enter care.
One of the major barriers to care in rural sub-Saharan
Africa is access to health facilities. In rural southern Zam-
bia, more than 90% of HIV-infected children travelled
more than one hour to the clinic and more than one quar-
ter travelled more than five hours. Lack of transportation,
insufficient financial resources and poor roads were com-
monly cited obstacles to accessing the clinic, particularly
during the rainy season. Such obstacles are unlikely to be
major barriers to care in urban settings and could result in
suboptimal treatment outcomes for HIV-infected children
residing in rural areas. Significantly more children not on
Table 2: Characteristics at study enrollment of HIV-infected children not receiving ART
Total (n = 138) Children not eligible for ARTc 
(n = 53)
Children eligible for ART at study 
enrollment (n = 79)
Median age (yrs) (IQR)a 3.3 (1.8, 6.7) 3.6 (2.5, 6.7) 2.3 (1.3, 6.7)
Male (%) 55 (40) 20 (38) 34 (43)
Length of time (months) since 
enrolling in ART clinic
3.2 (0.5, 10.1) 3.8 (0.2, 11.7) 2.8 (0.4, 9.0)
Median WAZ (IQR) (n = 120)a,b -2.2 (-3.2, -1.3) -2.1 (-2.7, -1.0) -2.4 (-3.5,-1.6)
WAZ <-2 66 (55) 25 (53) 41 (59)
WAZ ≥-2 54 (45) 22 (47) 28 (41)
Median CD4+ T cell % (IQR) (n = 
122)a
20.7 (16.0, 30.0) 29.6 (23.2, 36.9) 17.4 (12.1, 21.1)
Median CD4+ T cell count (IQR) (n = 
126)a
815 (455, 1372) 980 (578, 1434) 735 (377, 1287)
Severe immunodeficiencya,d 47 (37) 0 (0.0) 47 (64)
Median total lymphocyte count 
(IQR) (n = 73)
4266 (2238, 7025) 3289 (2179, 4847) 4464 (2328, 7236)
Median hemoglobin (IQR) (n = 110)a 10.5 (9.2,11.6) 11.3 (9.8,11.7) 10.1 (8.8, 11.3)
Hemoglobin <8 gm/dL 6 (5) 1 (3) 5 (7)
Hemoglobin ≥8 gm/dL 104 (95) 36 (97) 68 (93)
WHO stage (n = 101)a
1 17 (16) 11 (34) 5 (7)
2 33 (32) 21 (66) 10 (14)
3 38 (37) 0 (0) 38 (55)
4 16 (15) 0 (0) 16 (23)
ART = antiretroviral therapy; IQR = interquartile range; WAZ = weight-for-age Z score; WHO = World Health Organization
a p < 0.05 for difference between children eligible and ineligible for ART at study enrollment
b for children <10 yrs old
c eligibility for ART determined based on the 2006 WHO treatment guidelines; 6 children could not be classified as WHO stage and laboratory 
results were not available at baseline
d severe immunodeficiency defined by age according to WHO guidelinesBMC Infectious Diseases 2009, 9:169 http://www.biomedcentral.com/1471-2334/9/169
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ART reported problems accessing the clinic but the rea-
sons are unknown. It may be that caregivers who have
committed to providing ART for their child perceive fewer
problems, as the journey to and from the clinic has
become routine.
The majority of children (78%) were not receiving ART at
the time of study entry. Although these children were fol-
lowed for only a median of 3.2 months, some were
deemed eligible for ART at study entry. Over a third were
severely immunosuppressed and slightly more than half
were classified as WHO stage 3 or 4 at the initial study
visit. Consequently, many of these children were eligible
for ART at the study visit according to the WHO guide-
lines. However, many met criteria for WHO stage 3
because of poor nutritional status, which in this setting
does not necessarily represent advanced HIV disease and
is not in itself a criterion for treatment initiation. In addi-
tion, many children had not been followed in the clinic
long enough to fulfill the requirements for treatment ini-
tiation, including eligibility and adherence visits. For chil-
dren who had been in the clinic a sufficient time, delayed
initiation of ART could have resulted from biomedical,
social or health care-associated factors. In a study con-
ducted in Pretoria, South Africa, reasons for delayed initi-
ation of ART among 147 eligible, HIV-infected children
included: tuberculosis co-infection (26%); inadequate
clinic staffing (20%); social problems, including lack of
transportation, absence of legal guardian and denial
(17%); and inaccurate clinical or immunological staging
(14%) [27]. In this study, delays in initiation of ART most
frequently resulted from loss to follow-up or concurrent
tuberculosis. Given the advanced clinical and immuno-
logical stages at which children entered the clinic, delays
in ART initiation could be detrimental, leading to higher
pre-ART mortality [28], more rapid disease progression
[26], or poorer response to treatment.
In rural Zambia, three quarters of the HIV-infected chil-
dren seeking care had a parent as the primary caregiver,
although one third had lost at least one parent. Children
who are orphans [29] and children whose primary car-
egiver is not a parent [30] may be at increased risk for non-
adherence to the antiretroviral regimen. Few children,
even among the older age groups, were reported to be
aware of their HIV-infection status, primarily because the
caregivers thought the child too young to be told the diag-
nosis or they were afraid to tell the child. However, this
finding must be interpreted with caution as this informa-
tion was reported by the caregiver rather than the child
and may be an underestimate of the children's true knowl-
edge of their status.
Table 3: Characteristics of children receiving ART (n = 54)
At clinic enrollment At ART initiationa At study enrollment
Median age (yrs) (IQR) 3.6 (1.5, 7.7) 3.8 (2.0, 8.0) 4.5 (2.7, 8.6)
Median WAZ (IQR)b -2.7 (-3.5, -1.5) -2.5 (-3.9, -1.8) -2.4 (-3.2, -1.5)
WAZ <-2 27 (61.4) 28 (70.0) 26 (60.5)
WAZ ≥-2 17 (38.6) 12 (30.0) 17 (39.5)
Median CD4+ T cell % (IQR) 14.0 (9.2, 19.0) 12.4 (9.2, 18.6) 28.6 (23.5, 36.1)
Median CD4+ T cell count (IQR) 505 (281, 985) 368 (219, 559) 973 (466, 1522)
Severe immunodeficiencyc 16 (50) 24 (63) 2 (5)
Median total lymphocyte count (IQR) 3194 (1948, 5351) 2747 (1634, 5351) 3372 (1862, 5276)
Median hemoglobin (IQR) 10.6 (10.0, 11.7) 10.8 (10.0, 12.0) 11.9 (10.6, 12.3)
Hemoglobin <8 gm/dL 1 (2.0) 0 (0) 4 (8.9)
Hemoglobin ≥8 gm/dL 49 (98.0) 36 (100.0) 41 (91.1)
WHO stage
1 2 (5.1) 2 (7.1) 6 (17.7)
2 9 (23.1) 1 (3.6) 6 (17.7)
3 22 (56.4) 20 (71.4) 20 (58.8)
4 6 (15.4) 5 (17.9) 2 (5.9)
ART regimen
AZT/3TC/EFV --- 12 (26.1) 11 (42.3)
AZT/3TC/NVP --- 11 (23.9) 7 (26.9)
d4T/3TC/EFV --- 5 (10.8) 2 (7.7)
d4T/3TC/NVP --- 18 (39.1) 6 (23.1)
ART = antiretroviral therapy; IQR = interquartile range; WAZ = weight-for-age Z score; WHO = World Health Organization; AZT = zidovudine; 
3TC = lamivudine; EFV = efavirenz; NVP = nevirapine; d4T = stavudine
a7 children transferred to Macha and had already initiated ART
bfor children <10 yrs old
csevere immunodeficiency defined by age according to WHO guidelinesBMC Infectious Diseases 2009, 9:169 http://www.biomedcentral.com/1471-2334/9/169
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Despite these barriers, the 54 children receiving ART at
study entry achieved good immunological responses, with
the percentage of CD4+ T cells increasing a median of
17.6% after a median of 8.1 months of therapy. This com-
pares favorably with 28 published studies of the immuno-
logical response to ART among HIV-infected children in
sub-Saharan Africa residing largely in urban settings, in
which the median gain in percentage of CD4+ T cells was
7-14% at 6-8 months and 10-16% at 12-15 months of
therapy [6]. In contrast, weight gain among HIV-infected
children receiving ART in rural Zambia did not achieve the
levels reported elsewhere in sub-Saharan Africa, with WAZ
scores increasing a median of 0.24 after receiving ART a
median of 8.6 months. Among 17 published studies that
reported nutritional outcomes, weight-for-age Z scores
improved by 1 SD after twelve months of ART [6]. Simi-
larly, among 749 HIV-infected Ugandan children who
received ART for a mean of 6 months, the mean weight-
for-age Z score increased from -3.2 to -2.1 over the study
period [31]. HIV-infected children receiving ART in rural
sub-Saharan Africa may have poorer weight gain because
of lower dietary intake than children residing in urban
areas.
Conclusion
HIV-infected children in rural southern Zambia have long
travel times to access care and may have poorer weight
gain on ART than children in urban areas. Despite these
barriers, children in rural Zambia had a substantial rise in
CD4+ T cell counts in the first year of ART although longer
follow-up may indicate these gains are not sustained.
Developing strategies to improve access to care and nutri-
tion will be necessary to ensure optimal, long-term treat-
ment outcomes for HIV-infected children residing in rural
sub-Saharan Africa.
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